Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Hormone receptor-positive (HR+) advanced breast cancer remains a significant clinical challenge.
• Current treatment paradigms are evolving with targeted therapies and novel drug combinations.

Purpose of the Study:

• To review current management strategies for HR+ advanced breast cancer.
• To highlight ongoing clinical investigations and novel therapeutic agents in development.

Main Methods:

• Review of current clinical practice guidelines and recent clinical trial data.
• Analysis of emerging targeted therapies and combination treatment approaches.

Main Results:

• CDK4/6 inhibitors plus endocrine therapy are standard first-line treatment.
• Second-line options include continuing CDK4/6 inhibitors with alternative endocrine therapy or using endocrine therapy with PI3K/AKT pathway inhibitors.
• Novel oral SERDs and agents targeting specific mutations (e.g., ESR1) are under investigation.

Conclusions:

• Advances in HR+ advanced breast cancer treatment have improved patient outcomes.
• Further understanding of combination therapies, sequencing, and biomarker development is crucial for optimizing treatment paradigms and overcoming resistance.